<DOC>
	<DOCNO>NCT00179790</DOCNO>
	<brief_summary>Stem cell transplantation may use cure childhood cancer , disease . Traditionally , stem cell transplant use high dos chemotherapy radiation . This regimen may cause significant problem transplant infertility , infection , graft versus host disease ( GVHD ) . Reduced intensity transplant ( RIT ) use medication weaken immune system , allow donor cell take . The goal RIT reduce risk complication transplant . Usually medication use weaken immune system , option extracorporeal photopheresis ( ECP ) may less toxic . ECP currently use treatment GVHD certain lymphoma . ECP us machine filter white blood cell blood , treat ultraviolet ( UV ) light , give cell back patient . The patient 's immune system become weak , allow donor cell replace patient . Studies involve use ECP condition show few side effect use medication . The primary purpose clinical research trial evaluate safety feasibility ECP part preparative regimen RIT child young adult .</brief_summary>
	<brief_title>Reduced Intensity Transplant Using Extracorporeal Photopheresis</brief_title>
	<detailed_description>This study test feasibility reduce intensity preparative regimen stem cell transplant include extracorporeal photopheresis ( ECP ) , busulfan , fludarabine patient leukemia , lymphoma , certain non-malignant disease . The current reduced intensity protocol include busulfan , fludarabine , anti-thymocyte immunoglobulin . ECP currently use disease chronic GVHD cutaneous T cell lymphoma . The mechanism ECP define . It hypothesize exposure white blood cell ultraviolet light 8-methoxypsoralen initiate apoptotic cellular cascade . Apoptotic cell recognize remove reticuloendothelial system , initiate secretion anti-inflammatory cytokine reduction proinflammatory cytokine . Antigen present cell regulate immune response induction tolerance . Here incorporate use ECP , fludarabine , busulfan preparative regimen , follow ECP prophylaxis acute graft versus host disease . We hypothesize photopheresis safe feasible , patient similar rate engraftment less GVHD treat current reduced intensity protocol . The use ECP prior transplant provide immunosuppression promote host engraftment . Furthermore , introduction ECP follow transplant may able induce tolerance thereby reduce rate GVHD .</detailed_description>
	<criteria>Weight &gt; 25 kg Patients acute lymphoblastic leukemia ( ALL ) CR ( complete remission ; &lt; 5 % blast bone marrow active central nervous system disease ) : Are second remission initial remission &lt; 36 month . Patients `` high risk '' disease CR1 , define karyotype abnormality presence ( 9 ; 22 ) translocation , monosomy 7 , monosomy 5 ; and/or patient slow initial response ( initial remission reach within four week diagnosis ) . Are third ( subsequent ) remission Experience isolate extramedullary relapse therapy Have experience relapse follow myeloablative stem cell transplant Are WT1+ follow induction therapy Patients acute myelogenous leukemia ( AML ) : Are first remission remain WT1 positive . Are second remission Are initial partial remission ( &lt; 20 % blast bone marrow ) Experience relapse follow myeloablative stem cell transplant Patients relapse lymphoma whose residual disease appear chemoresponsive nonbulky ( &lt; 5 cm large diameter ) Patients chronic myelogenous leukemia ( CML ) chronic phase : Do n't achieve remission ( molecular cytogenetic ) 1 year diagnosis therapy ( imatinib mesylate interferon ) Have rise quantitative bcr/abl imatinib mesylate ( molecular relapse ) Had develop accelerate phase regardless therapy back second chronic phase Patients recurrent solid tumor ( neuroblastoma , Ewing 's sarcoma , melanoma , rhabdomyosarcoma ) Patients myelodysplastic syndrome Patients refractory anemia ( RA ) refractory anemia excess blast ( RAEB ) eligible , refractory anemia excess blast transformation ( RAEBT ) patient eligible treat &lt; 20 % blast chemotherapy Patients select immunodeficiency WiskottAldrich syndrome hyperIgM syndrome Patients metabolic disease NiemannPick adrenoleukodystrophy Patients bone marrow failure syndrome , include aplastic anemia Adequate venous access</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>hemoglobinopathy</keyword>
	<keyword>immune deficiency</keyword>
	<keyword>photopheresis</keyword>
	<keyword>ECP</keyword>
	<keyword>extracorporeal photopheresis</keyword>
</DOC>